ESTUTC-5 New YorkLog in Sign up

FATE
Fate Therapeutics, Inc.
stockNASDAQ

At CloseOct 30, 2026 2:17:38 PM EDT

2.05USD-5.760%(-0.12)1,064,419

Pre-marketOct 30, 2026 10:23:50 AM EDT

2.04USD-6.221%(-0.14)

FATE News

Day breaks

03:12 PM EDTRussell 2000 estimated to add 107 stocks in December rebalance - Stephens ·

Seeking Alpha

07:18 AM EDTOlaniwun Ajayi LP appoints former FATE Foundation CEO Adenike Adeyemi as new Chief Executive ·

Nairametrics

07:04 AM EDTFate Therapeutics appoints Jamie Harrell to lead commercialization ·

Investing.com

07:04 AM EDTFate Therapeutics appoints Jamie Harrell to lead commercial strategy ·

Investing.com

07:00 AM EDTFate Therapeutics Appoints Jamie Harrell as Senior Vice President, Market Development & Commercial Operations to Lead the Commercialization of CAR T-cell Therapies ·

GlobeNewswire Inc.

07:00 AM EDTFate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) ·

GlobeNewswire Inc.

07:00 AM EDTFate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences ·

GlobeNewswire Inc.

07:04 AM EDTFate Therapeutics receives $15m CIRM grant for lupus trial ·

Investing.com

07:00 AM EDTFate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN ·

GlobeNewswire Inc.

07:00 AM EDTFate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026 ·

GlobeNewswire Inc.

01:00 PM EDTLupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsight ·

GlobeNewswire Inc.